Migraine: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• CGRP 19
• HMGB1 0
• NOTCH3 0
• GLP-1 0
• MAPK 0
• PI3K 0
• IL-17 0
• IL-6 1
• TNF 1
• PPAR 0
• TREM2 0
• COX-2 0
• IL-4 0
• STING 0
• AKT 0
• AMPK 0
• AQP4 0
• ERK 0
• GIP 0
• GPX4 0
• HIF-1 0
• IL-1 1
• mTOR 0
• NLRP3 0
• NMDA 0
• PD-1 0
• SCN1A 0
• SCN2A 0
• STAT3 0
• VEGF 0

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 200+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  A Study of K-645 in the Treatment of Multiple Migraine Attacks

  NCT07116499· TriGemX Bio, Inc.· Updated 5 Nov 2026

  “Study stopped for futility based on an interim analysis of efficacy.”Registry text, quoted unchanged. Source

• Withdrawn

  EMBRACE Study: Enduring Migraine Benefit From Responsive Artery Coil Embolization

  NCT07313800· Cortex Neurovascular· Updated 27 Oct 2026

  “The study was not initiated. IRB review determined the study would require an investigational device exemption (IDE), and the sponsor elected not to proceed because resources were not available. No subjects were enrolled.”Registry text, quoted unchanged. Source

• Suspended

  Management of Acute Tinnitus With Migraine Medications

  NCT06799169· University of California, Irvine· Updated 27 Oct 2026

  “Enrollment temporarily paused pending IRB continuing review; recruitment expected to resume.”Registry text, quoted unchanged. Source

• Terminated

  Migraine and CVD Risk in Women

  NCT03081390· University of Pennsylvania· Updated 6 Oct 2026

  “Investigator transition”Registry text, quoted unchanged. Source

• Withdrawn

  Oral Medications for the Management of Acute Migraine Headache in the Emergency Department

  NCT05983354· Health Sciences North Research Institute· Updated 5 Oct 2026

  “The project proved not feasible to launch at Health Sciences North.”Registry text, quoted unchanged. Source

• Suspended

  A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease

  NCT04031469· ProgenaBiome· Updated 21 Sept 2026

  “Administrative”Registry text, quoted unchanged. Source

• Terminated

  Computer Game, Qualitative, and MEG/EEG Assessment of Serotonergic Psychedelics

  NCT06624137· Yale University· Updated 9 Jul 2026

  “Funding ended.”Registry text, quoted unchanged. Source

• Terminated

  GORE® CARDIOFORM Septal Occluder Migraine Clinical Study

  NCT04100135· W.L.Gore & Associates· Updated 9 Jun 2026

  “Dissatisfactory enrollment rate with no safety concerns”Registry text, quoted unchanged. Source

• Terminated

  Acute Migraine Treatment in the ED With Gepants

  NCT06985342· Icahn School of Medicine at Mount Sinai· Updated 29 Apr 2026

  “Study closing at current site. Study to start as new at different site.”Registry text, quoted unchanged. Source

• Suspended

  Vibratory Stimulation for the Treatment of Chronic Pain

  NCT04069572· Stanford University· Updated 24 Apr 2026

  “New investigational devices are currently under development.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Marine Lipids Ease Painful TMD

  NCT07437313· University of North Carolina, Chapel Hill· Source

• App-Based Migraine Treatment: The Health enSuite Study

  NCT06797076· IWK Health Centre· Source

• Migraine Menopause Study

  NCT07916571· Alberta Neurologic Centre· Source

• MMA Embolization for Refractory Chronic Migraine

  NCT06735833· Cerenovus, Part of DePuy Synthes Products, Inc.· Source

• Treatment for Migraine and Mood

  NCT05576467· Amanda Shallcross· Source

• Cocoa Extract for Migraine Trial

  NCT06808230· Brigham and Women's Hospital· Source

• Eary Infusion of Eptinezumab for TreatmEnt of ACute Post-Traumatic Headaches (ELITE-ACT)

  NCT07191145· Sunnybrook Health Sciences Centre· Source

• Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine

  NCT03832998· Amgen· Source

• A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participants With Episodic Migraine

  NCT06602479· AbbVie· Source

• Randomized Study in Children and Adolescents With Migraine: Acute Treatment

  NCT04649242· Pfizer· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 7
• Mendelian Randomization Analysis 33
• Gene Expression Profiling 8
• Sequence Analysis, RNA 2
• Exome Sequencing 5
• Proteomics 6
• Metabolomics 6
• Mass Spectrometry 1
• Xenograft Model Antitumor Assays 2
• Positron-Emission Tomography 3
• Magnetic Resonance Imaging 136
• Machine Learning 32
• Deep Learning 1
• Cohort Studies 82
• Genome-Wide Association Study 40

• Peripheral CD4 T-Cell State Remodeling in Migraine Revealed by Single-Cell RNA Sequencing.

  J Mol Neurosci, Aug 2026

• Single-cell RNA-sequencing reveals cellular heterogeneity and identifies biomarkers for obstructive sleep apnea and migraine.

  Hum Genomics, May 2026

• Causal cross-trait mapping at single-cell resolution identifies shared immunogenetic drivers of migraine and Meniere's disease.

  J Headache Pain, Apr 2026

• Peripheral Immune and Metabolic Dysregulation in Migraine, Ménière's Disease, and Vestibular Migraine: A Single-Cell Atlas Study.

  Hum Mutat, Apr 2026

• Unraveling the Cross-Tissue Neuroimmune-Vascular Genetic Architecture of Migraine Using Integrated Multi-Omics, Single-Cell, and Spatial Transcriptomics: Prioritizing T-Cell Regulatory Networks and Peripheral Targets.

  Int J Mol Sci, Feb 2026

• Mapping the brain cell-specific regulatory architecture of migraine: a single-cell causal framework nominating inhibitory-neuronal BTBD16 and astrocytic RIMS1 as therapeutic targets.

  J Headache Pain, Dec 2025

• A single-cell multi-omics framework identifies immune cell drivers of migraine and repurposable therapeutics.

  J Headache Pain, Nov 2025

See which targets of this disease your abstract mentions, and go to the people working on them.